- Home
- MPTI vs ZNTL Comparison
MPTI vs ZNTL Comparison
Compare MPTI & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPTI
- ZNTL
- Stock Information
- Founded
- MPTI 1965
- ZNTL 2014
- Country
- MPTI United States
- ZNTL United States
- Employees
- MPTI N/A
- ZNTL N/A
- Industry
- MPTI
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- MPTI
- ZNTL Health Care
- Exchange
- MPTI Nasdaq
- ZNTL Nasdaq
- Market Cap
- MPTI 127.2M
- ZNTL 105.8M
- IPO Year
- MPTI N/A
- ZNTL 2020
- Fundamental
- Price
- MPTI $47.33
- ZNTL $1.49
- Analyst Decision
- MPTI
- ZNTL Buy
- Analyst Count
- MPTI 0
- ZNTL 7
- Target Price
- MPTI N/A
- ZNTL $8.46
- AVG Volume (30 Days)
- MPTI 30.8K
- ZNTL 805.4K
- Earning Date
- MPTI 11-12-2025
- ZNTL 11-11-2025
- Dividend Yield
- MPTI N/A
- ZNTL N/A
- EPS Growth
- MPTI 45.88
- ZNTL N/A
- EPS
- MPTI 2.57
- ZNTL N/A
- Revenue
- MPTI $52,033,000.00
- ZNTL $26,865,000.00
- Revenue This Year
- MPTI $11.34
- ZNTL N/A
- Revenue Next Year
- MPTI $8.04
- ZNTL N/A
- P/E Ratio
- MPTI $18.32
- ZNTL N/A
- Revenue Growth
- MPTI 16.52
- ZNTL N/A
- 52 Week Low
- MPTI $27.97
- ZNTL $1.01
- 52 Week High
- MPTI $60.00
- ZNTL $5.44
- Technical
- Relative Strength Index (RSI)
- MPTI 59.47
- ZNTL 43.18
- Support Level
- MPTI $44.41
- ZNTL $1.60
- Resistance Level
- MPTI $48.91
- ZNTL $2.02
- Average True Range (ATR)
- MPTI 1.55
- ZNTL 0.13
- MACD
- MPTI 0.33
- ZNTL -0.04
- Stochastic Oscillator
- MPTI 71.03
- ZNTL 5.36
About MPTI M-tron Industries Inc.
M-Tron Industries Inc is a diversified holding company with subsidiaries engaged in designing, manufacturing, and marketing high-engineered, high-reliability frequency and spectrum control products used to control the frequency or timing of signals in electronic circuits in various applications. The company's serving markets are aerospace and defense, space, and avionics. The company offers products such as microwave and millimeter wave filters; cavity, crystal, ceramic, lumped element, and switched filters; crystal resonators, integrated microwave assemblies, and solid-state power amplifier products.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.